EUVIMEDEUVIMED entdecken
Open Access

Assessment of the activity and mechanisms of resistance to cefiderocol and combinations of β-lactams and the novel β-lactamase inhibitors avibactam, taniborbactam, zidebactam, nacubactam, xeruborbactam, and ANT3310 in emerging double-carbapenemase-producing Enterobacterales

Tania Blanco-Martín iD, Inmaculada López-Hernández, Belén Aracil, Lucía González-Pinto, Pablo Aja-Macaya, Isaac Alonso-García, Salud Rodríguez-Pallares, Lucía Sánchez-Peña, Michelle Outeda-García, María Pérez-Vázquez, Juan Carlos Vázquez-Ucha, Alejandro Beceiro iD und 6 weitere

Antimicrobial Agents and Chemotherapy · 06.11.2024 · 68 (11)

DOI: 10.1128/aac.00924-24 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Antimicrobial Agents and Chemotherapy, erschienen am 06.11.2024. Verfasst von Tania Blanco-Martín und 17 weiteren Autor:innen. Beteiligte Einrichtung: Servicio de Microbiología Clínica e Instituto de Investigación Biomédica A Coruña (INIBIC), Complexo Hospitalario Universitario A Coruña, A Coruña, S…. Hauptthemen laut MEDLINE: Microbial Sensitivity Tests, Azabicyclo Compounds, beta-Lactamases, Anti-Bacterial Agents. Die Arbeit wurde bisher 30-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: MEC | Instituto de Salud Carlos III (ISCIII), Axencia Galega de Innovación (GAIN), Centro de Investigación Biomédica en Red de Enfermedades Infecciosas (CIBERINFEC).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

We aimed to investigate the activity of and mechanisms of resistance to cefiderocol and innovative β-lactam/β-lactamase inhibitor combinations in a nationwide collection of double-carbapenemase-producing Enterobacterales. In all, 57 clinical isolates co-producing two carbapenemases collected from Spanish hospitals during the period 2017–2022 were analyzed. Minimum inhibitory concentration (MIC) values for ceftazidime, ceftazidime/avibactam, aztreonam, aztreonam/avibactam, aztreonam/nacubactam, cefiderocol, cefepime, cefepime/taniborbactam, cefepime/zidebactam, cefepime/nacubactam, imipenem, imipenem/relebactam, meropenem, meropenem/vaborbactam, meropenem/xeruborbactam, and meropenem/ANT3310 were determined by reference broth microdilution. Genetic drivers of resistance were analyzed by whole-genome sequencing (WGS). The collection covered nine carbapenemase associations: VIM + OXA-48 (21/57), NDM + OXA-48 (11/57), KPC + VIM (10/57), KPC + OXA-48 (6/57), IMP + OXA-48 (3/57), NDM + KPC (2/57), NDM + VIM (2/57), NDM + GES (1/57), and KPC + IMP (1/57). Ceftazidime/avibactam, imipenem/relebactam, and meropenem/vaborbactam were the least active options. Aztreonam/avibactam and aztreonam/nacubactam were active against the whole collection and yielded MIC 50 /MIC 90 values of ≤0.25/0.5 mg/L and 1/2 mg/L, respectively. Cefepime/zidebactam (56/57 susceptible), meropenem/xeruborbactam (56/57 susceptible), cefepime/nacubactam (55/57 susceptible), and cefiderocol (53/57 susceptible) were also highly active, with MIC 50 /MIC 90 values ranging from ≤0.25–2 mg/L to 2–4 mg/L, respectively. Meropenem/ANT3310 (MIC 50 /MIC 90 = 0.5/≥64 mg/L; 47/57 susceptible) and cefepime/taniborbactam (MIC 50 /MIC 90 = 0.5/16 mg/L; 44/57 susceptible) also retained high levels of activity, although they were affected by NDM-type enzymes in combination with porin deficiency. Our findings highlight that cefiderocol and combinations of β-lactams and the novel β-lactamase inhibitors avibactam, nacubactam, taniborbactam, zidebactam, xeruborbactam, and ANT3310 show promising activity against double-carbapenemase-producing Enterobacterales.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Microbial Sensitivity TestsAzabicyclo Compoundsbeta-LactamasesAnti-Bacterial Agentsbeta-Lactamase InhibitorsBacterial ProteinsCephalosporinsHeterocyclic Compounds, 1-RingCefiderocolBoronic AcidsCeftazidimeCyclooctanesHumansDrug CombinationsCefepimeBorinic AcidsAztreonambeta-LactamsCarbapenem-Resistant EnterobacteriaceaeEnterobacteriaceaeDrug Resistance, Multiple, BacterialCarboxylic AcidsLactamsPiperidines

Stichwörter der Autor:innen

Enterobacteralesantimicrobial resistancecarbapenemasecefiderocoldouble carbapenemaseβ-lactamaseβ-lactamase inhibitor

Substanzen

Azabicyclo Compoundsbeta-LactamasesAnti-Bacterial Agentsbeta-Lactamase InhibitorscarbapenemaseBacterial ProteinsCephalosporinsHeterocyclic Compounds, 1-Ringtaniborbactamzidebactam

Autor:innen und Institutionen

  • Servicio de Microbiología Clínica e Instituto de Investigación Biomédica A Coruña (INIBIC), Complexo Hospitalario Universitario A Coruña, A Coruña, Spain.
  • Laboratorio de Referencia para tipado molecular y detección de mecanismos de resistencia a antimicrobianos de Andalucía (PIRASOA). Unidad de Gestión Clínica de Microbiología y Enfermedades Infecciosas, Hospital Universi…
  • CIBER de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III, Madrid, Spain.
  • Laboratorio de Referencia e Investigación en Resistencia a Antibióticos e Infecciones relacionadas con la Asistencia Sanitaria, Centro Nacional de Microbiología, Instituto de Salud Carlos III, Majadahonda, Madrid, Spain.

ORCID-Profile: Tania Blanco-Martín, Alejandro Beceiro, Germán Bou, Lorena López-Cerero, Jorge Arca-Suárez

Förderung

  • MEC | Instituto de Salud Carlos III (ISCIII)
  • Axencia Galega de Innovación (GAIN)
  • Centro de Investigación Biomédica en Red de Enfermedades Infecciosas (CIBERINFEC)

Zitieren

APA

Blanco-Martín, T., López-Hernández, I., Aracil, B., González-Pinto, L., Aja-Macaya, P., Alonso-García, I., Rodríguez-Pallares, S., Sánchez-Peña, L., Outeda-García, M., Pérez-Vázquez, M., Vázquez-Ucha, J. C., Beceiro, A., Pascual, Á., Bou, G., López-Cerero, L., Oteo-Iglesias, J., Arca-Suárez, J., & GEMARA-SEIMC/CIBERINFEC Study Group on the activity and resistance mechanisms to new β-lactams and β-lactamase inhibitors (PROTECT) (2024). Assessment of the activity and mechanisms of resistance to cefiderocol and combinations of β-lactams and the novel β-lactamase inhibitors avibactam, taniborbactam, zidebactam, nacubactam, xeruborbactam, and ANT3310 in emerging double-carbapenemase-producing Enterobacterales. Antimicrobial Agents and Chemotherapy, 68(11). https://doi.org/10.1128/aac.00924-24

Vancouver

Blanco-Martín T, López-Hernández I, Aracil B, González-Pinto L, Aja-Macaya P, Alonso-García I, et al. Assessment of the activity and mechanisms of resistance to cefiderocol and combinations of β-lactams and the novel β-lactamase inhibitors avibactam, taniborbactam, zidebactam, nacubactam, xeruborbactam, and ANT3310 in emerging double-carbapenemase-producing Enterobacterales. Antimicrobial Agents and Chemotherapy. 2024;68(11). doi:10.1128/aac.00924-24

BibTeX
@article{BlancoMartn2024,
  author = {Blanco-Martín, Tania and López-Hernández, Inmaculada and Aracil, Belén and González-Pinto, Lucía and Aja-Macaya, Pablo and Alonso-García, Isaac and Rodríguez-Pallares, Salud and Sánchez-Peña, Lucía and Outeda-García, Michelle and Pérez-Vázquez, María and Vázquez-Ucha, Juan Carlos and Beceiro, Alejandro and Pascual, Álvaro and Bou, Germán and López-Cerero, Lorena and Oteo-Iglesias, Jesús and Arca-Suárez, Jorge and GEMARA-SEIMC/CIBERINFEC Study Group on the activity and resistance mechanisms to new β-lactams and β-lactamase inhibitors (PROTECT), GEMARA-SEIMC/CIBERINFEC Study Group on the activity and resistance mechanisms to new β-lactams and β-lactamase inhibitors (PROTECT)},
  title = {Assessment of the activity and mechanisms of resistance to cefiderocol and combinations of β-lactams and the novel β-lactamase inhibitors avibactam, taniborbactam, zidebactam, nacubactam, xeruborbactam, and ANT3310 in emerging double-carbapenemase-producing Enterobacterales},
  journal = {Antimicrobial Agents and Chemotherapy},
  year = {2024},
  volume = {68},
  number = {11},
  doi = {10.1128/aac.00924-24}
}
Kostenlos starten →